{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:29:31Z","timestamp":1791275371089,"version":"4.1.0"},"reference-count":181,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Chem."],"DOI":"10.3389\/fchem.2014.00050","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T14:11:43Z","timestamp":1406038303000},"source":"Crossref","is-referenced-by-count":41,"title":["Human isoprenoid synthase enzymes as therapeutic targets"],"prefix":"10.3389","volume":"2","author":[{"given":"Jaeok","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexios N.","family":"Matralis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert M.","family":"Berghuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youla S.","family":"Tsantrizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0022-3565(24)36653-4","article-title":"RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase","volume":"281","author":"Amin","year":"1997","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"B2","volume-title":"Quinolines as Inhibitors of Farnesyl Pyrophosphate Synthase","author":"Amstutz","year":"2009"},{"key":"B3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.addr.2004.12.014","article-title":"Targeting of therapeutic agents to bone to treat metastatic cancer","volume":"57","author":"Bagi","year":"2005","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1016\/j.bmc.2010.08.036","article-title":"Synthesis and biological evaluation of a series of aromatic bisphosphonates","volume":"18","author":"Barney","year":"2010","journal-title":"Bioorg. Med. Chem"},{"key":"B5","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1016\/S0021-9258(19)49754-8","article-title":"Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo","volume":"267","author":"Baxter","year":"1992","journal-title":"J. Biol. Chem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6249","DOI":"10.1158\/1078-0432.CCR-12-0918","article-title":"In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors Trigger V\u00ce\u00b39V\u00ce\u00b4 2 T-cell antitumor cytotoxicity through ICAM-1 engagement","volume":"18","author":"Benza\u00c3\u00afd","year":"2012","journal-title":"Clin. Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1073\/pnas.90.1.80","article-title":"Zaragosic acids:a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase","volume":"90","author":"Bergstrom","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0960-894X(01)81236-1","article-title":"Aromatic isosters as conformational probes for an isoprenyl subunit: application to inhibitors of squalene synthase","volume":"3","author":"Biller","year":"1993","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1021\/jm00110a024","article-title":"Isoprenyl phosphinylformates: new inhibitors of squalene synthetase","volume":"34","author":"Biller","year":"1991","journal-title":"J. Med. Chem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1021\/jm00021a003","article-title":"Phenoxypropylamines: a new series of squalene synthase inhibitors","volume":"38","author":"Brown","year":"1995","journal-title":"J. Med. Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1021\/jm950907l","article-title":"Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors","volume":"39","author":"Brown","year":"1996","journal-title":"J. Med. Chem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0960-894X(97)00053-X","article-title":"Novel optimised quinuclidine squalene synthase inhibitors","volume":"7","author":"Brown","year":"1997","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/prot.22066","article-title":"Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases","volume":"73","author":"Cao","year":"2008","journal-title":"Proteins"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1021\/mp3006215","article-title":"Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain","volume":"10","author":"Caraglia","year":"2013","journal-title":"Mol. Pharm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1021\/jm9504969","article-title":"The squalestatins: decarboxyand 4-deoxy analogues as potent squalene synthase inhibitors","volume":"39","author":"Chan","year":"1996","journal-title":"J. Med. Chem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1194\/jlr.M026161","article-title":"Inhibitors of protein geranylgeranyltransferase-I lead to prelamin A accumulation in cells by inhibiting ZMPSTE24","volume":"53","author":"Chang","year":"2012","journal-title":"J. Lipid Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt1273","article-title":"Structure-based maximal affinity model predicts small-molecule druggability","volume":"25","author":"Cheng","year":"2007","journal-title":"Nat. Biotechnol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/jm991039l","article-title":"Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity","volume":"43","author":"Chrysselis","year":"2000","journal-title":"J. Med. Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1021\/jm011062i","article-title":"Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents","volume":"45","author":"Chrysselis","year":"2002","journal-title":"J. Med. Chem"},{"key":"B21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/039463201102400116","article-title":"Zoledronic acid enhances V\u00ce\u00b4 2 T-lymphocyte antitumor response to human glioma cell lines","volume":"24","author":"Cimini","year":"2011","journal-title":"Int. J. Immunopathol. Pharmacol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"24832","DOI":"10.1016\/S0021-9258(19)74540-2","article-title":"Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo","volume":"268","author":"Ciosek","year":"1993","journal-title":"J. Biol. Chem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"B25","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1016\/S0021-9258(18)99800-5","article-title":"Studies on the biosynthesis of cholesterol. XX. Steric course of decarboxylation of 5-pyrophosphomevalonate and of the carbon to carbon bond formation in the biosynthesis of farnesyl pyrophosphate","volume":"241","author":"Cornforth","year":"1966","journal-title":"J. Biol. Chem"},{"key":"B26","volume-title":"Salicylic Acid Derivatives Being Farnesyl Pyrophosphate Synthase Activity Inhibitors","author":"Cotesta","year":"2010"},{"key":"B27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.chembiol.2010.05.011","article-title":"Targeting the undruggable proteome: the small molecules of my dreams","volume":"17","author":"Crews","year":"2010","journal-title":"Chem. Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.bbagen.2012.07.013","article-title":"Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid","volume":"1820","author":"Dedes","year":"2012","journal-title":"Biochem. Biophys. Acta"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.1021\/jm500629e","article-title":"Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase \u00e2\u20ac\u201c implications to drug discovery for neurodegenerative diseases","volume":"57","author":"De Schutter","year":"2014","journal-title":"J. Med. Chem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1016\/j.bmc.2012.07.019","article-title":"Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active Site \u00e2\u20ac\u0153Capping\u00e2\u20ac\u009d phenyls","volume":"20","author":"De Schutter","year":"2012","journal-title":"Bioorg. Med. Chem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive mjeasures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1399-0004.2008.01099.x","article-title":"Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway","volume":"75","author":"Do","year":"2009","journal-title":"Clin. Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s10637-010-9446-y","article-title":"Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration","volume":"29","author":"Dudakovic","year":"2011","journal-title":"Invest. New Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.2174\/138161210793563617","article-title":"Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition","volume":"16","author":"Dunford","year":"2010","journal-title":"Curr. Pharm. Des"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1021\/jm7015733","article-title":"Structure-activity relationship among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase","volume":"51","author":"Dunford","year":"2008","journal-title":"J. Med. Chem"},{"key":"B36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationship for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bone.2011.02.011","article-title":"Bisphosphonates for postmenopausal osteoporosis","volume":"49","author":"Eastell","year":"2011","journal-title":"Bone"},{"key":"B38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","article-title":"The relationship between the chemistry and biological activity of the bisphosphonates","volume":"49","author":"Ebetino","year":"2011","journal-title":"Bone"},{"key":"B39","volume-title":"4-Azaindole Bisphosphonates","author":"Ebetino","year":"2010a"},{"key":"B40","volume-title":"5-Azaindole Bisphosphonates","author":"Ebetino","year":"2010b"},{"key":"B41","volume-title":"Imidazo[1,2-\u00ce\u00b1]pyridinyl Bisphosphonates","author":"Ebetino","year":"2010c"},{"key":"B42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.nbd.2009.05.005","article-title":"Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients","volume":"35","author":"Eckert","year":"2009","journal-title":"Neurobiol. Dis"},{"key":"B43","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","article-title":"The discovery and development of HMG-CoA reductase inhibitors","volume":"33","author":"Endo","year":"1992","journal-title":"J. Lipid Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1021\/jm980645y","article-title":"Peptide prodrug approach for improving bisphosphonate oral absorption","volume":"43","author":"Ezra","year":"2000","journal-title":"J. Med. Chem"},{"key":"B45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1593\/neo.10282","article-title":"How do bisphosphonates inhibit bone metastasis in vivo.","volume":"12","author":"Fournier","year":"2010","journal-title":"NeoPlasia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0167-5273(02)00577-6","article-title":"A comparative study of the in vitro antioxidant activity of statins","volume":"90","author":"Franzoni","year":"2003","journal-title":"Int. J. Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"m166","DOI":"10.1107\/S0108270110017634","article-title":"Zoledronate complexes. III. Two zoledronate complexes with alkaline earth metals: [Mg(C5H9N2O7P2)2(H2O)2] and [Ca(C5H8N2O7P2)(H2O)]n","volume":"66","author":"Freire","year":"2010","journal-title":"Acta Cryst. C"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2107-2116","DOI":"10.1007\/s00198-011-1805-9","article-title":"Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women","volume":"23","author":"Frost","year":"2012","journal-title":"Osteoporos Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1021\/jm970058x","article-title":"[(1-alpha, 2-beta, 3-beta, 4-alpha)-1,2-bis[N-propyl-N- (4-phenoxybenzyl)amino]carbonyl]cyclobutane -3,4-dicarboxylic acid (A-87049): a novel potent squalene synthase inhibitor","volume":"40","author":"Fung","year":"1997","journal-title":"J. Med. Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/prot.20754","article-title":"Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design","volume":"62","author":"Gabelli","year":"2006","journal-title":"Proteins"},{"key":"B51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jconrel.2013.01.032","article-title":"Biomedical applications of bisphosphonates","volume":"167","author":"Giger","year":"2013","journal-title":"J. Control. Release"},{"key":"B52","first-page":"295","article-title":"Rhabdomyolysis induced by simvastatin and ketoconazole treatment","volume":"22","author":"Gilad","year":"1999","journal-title":"Clin. Neuropharmacol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1089\/adt.2007.057","article-title":"Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay","volume":"5","author":"Glickman","year":"2007","journal-title":"Assay Drug Dev. Technol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"endocrine therapy plus zoledronic acid in premenopaisal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"New Engl. J. Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1210\/jc.2008-2241","article-title":"The antiresorptive effects of a single dose of zoledronate persists for two years: arandomized placebo-control trial in osteopenic postmenopausal women","volume":"94","author":"Grey","year":"2009","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B57","doi-asserted-by":"publisher","first-page":"10022","DOI":"10.1073\/pnas.0702254104","article-title":"Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases","volume":"104","author":"Guo","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B58","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J. Bone Miner. Res"},{"key":"B59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0140-6736(96)09328-2","article-title":"Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study","volume":"349","author":"Hoffman","year":"1997","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/bj1040057","article-title":"The purification of 3,3-dimethylallyl- and geranyl-transferase and of isopentenyl pyrophosphate isomerase from pig liver","volume":"104","author":"Holloway","year":"1967","journal-title":"Biochem. J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12035-012-8285-6","article-title":"brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice","volume":"46","author":"Hooff","year":"2012","journal-title":"Mol. Neurobiol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.bbalip.2010.03.014","article-title":"Isoprenoids, small GTPases and Alzheimer's disease","volume":"1801","author":"Hooff","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer's disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J. Neurochem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"8526","DOI":"10.1074\/jbc.C300511200","article-title":"Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis","volume":"279","author":"Hosfield","year":"2004","journal-title":"J. Biol. Chem"},{"key":"B65","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1046\/j.1445-5994.2002.00264.x","article-title":"HMG CoA reductase inhibitor-related myopathy and the influence of drug interactions","volume":"32","author":"Huynh","year":"2002","journal-title":"Intern. Med. J"},{"key":"B182","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1016\/j.bmc.2012.02.054","article-title":"Discovery of novel tricyclic compounds as squalene synthase inhibitors","volume":"20","author":"Ichikawa","year":"2012","journal-title":"Bioorg. Med. Chem"},{"key":"B66","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1021\/ml400151c","article-title":"Discovery of DF-461, a Potent Squalene Synthase Inhibitor","volume":"4","author":"Ichikawa","year":"2013","journal-title":"ACS Med. Chem. Lett"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.bmc.2011.01.065","article-title":"Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors","volume":"19","author":"Ichikawa","year":"2011","journal-title":"Bioorg. Med. Chem"},{"key":"B67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejphar.2010.05.010","article-title":"Pamidronate inhibits antiapoptotic bcl-2 expression though inhibition of the mevalonate pathway in prostate cancer PC-3 cells","volume":"641","author":"Iguchi","year":"2010","journal-title":"Eur. J. Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.1016\/j.bmc.2004.08.033","article-title":"Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors","volume":"12","author":"Ishihara","year":"2004","journal-title":"Bioorg. Med. Chem"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/0960-894X(95)00339-U","article-title":"Synthesis and biological activity of J-104118, a novel potent inhibitor of squalene synthase","volume":"5","author":"Iwasawa","year":"1995","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B70","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cmdc.201000016","article-title":"An in vitro assay to measure targeted drug delivery to bone mineral","volume":"5","author":"Jahnke","year":"2010","journal-title":"ChemMedChem"},{"key":"B71","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nchembio.421","article-title":"Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery","volume":"6","author":"Jahnke","year":"2010","journal-title":"Nat. Chem. Biol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"Jick","year":"2000","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrm2941","article-title":"The HSP70 chaperone machinery J proteins as drivers of functional specificity","volume":"11","author":"Kampinga","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"22004","DOI":"10.1074\/jbc.M602603200","article-title":"The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding","volume":"281","author":"Kavanagh","year":"2006b","journal-title":"J. Biol. Chem"},{"key":"B74","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006a","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B76","doi-asserted-by":"publisher","first-page":"12479","DOI":"10.1073\/pnas.0403413101","article-title":"A tagging-via-substrate technology for detection and proteomics of farnesylated proteins","volume":"101","author":"Kho","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B77","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1016\/j.bmc.2010.09.008","article-title":"Design of more potent squalene synthase inhibitors with multiple activities","volume":"18","author":"Kourounakis","year":"2010","journal-title":"Bioorg. Med. Chem"},{"key":"B78","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.poly.2008.10.030","article-title":"X-ray diffraction study of bisphosphonate metal complexes: Mg, Sr and Ba complexes of (dichloromethylene)bispho-sphonic acid P,P'-dibenzoyl anhydride","volume":"28","author":"Kunnas-Hiltunen","year":"2009","journal-title":"Polyhedron"},{"key":"B79","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM199903043400914","article-title":"\u00ce\u00b3\u00ce\u00b4 T-Cell Stimulation by Pamidronate","volume":"340","author":"Kunzmann","year":"1999","journal-title":"N. Engl. J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1021\/jm400101e","article-title":"New Multifunctional di-tert-butyl-phenol-octahydro(pyrido\/benz)oxazine Deri- vatives with antioxidant, antihyperlipidemic and antidiabetic action","volume":"56","author":"Ladopoulou","year":"2013","journal-title":"J. Med. Chem"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"B83","doi-asserted-by":"publisher","first-page":"11668","DOI":"10.1021\/ja962505o","article-title":"Enantioselective synthesis of \u00ce\u00b1-phosphono sulfonate squalene synthase inhibitors: chiral recognition in the interactions of an \u00ce\u00b1-phosphono sulfonate inhibitor with squalene synthase","volume":"118","author":"Lawrence","year":"1996","journal-title":"J. Am. Chem. Soc"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/sj.onc.1201296","article-title":"Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines","volume":"15","author":"Lerner","year":"1997","journal-title":"Oncogene"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1016\/j.bmc.2013.02.006","article-title":"Discovery of thienopyrimidine-based inhibitors of the human farnesyl pyrophosphate synthase \u00e2\u20ac\u201c Parallel synthesis of analogs via a thrimethylsilyl ylidene intermediate","volume":"21","author":"Leung","year":"2013a","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B86","doi-asserted-by":"publisher","first-page":"7939","DOI":"10.1021\/jm400946f","article-title":"Thienopyrimidine Bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition","volume":"56","author":"Leung","year":"2013b","journal-title":"J. Med. Chem"},{"key":"B87","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1345\/aph.1G409","article-title":"Considerations for supplementing with coenzyme Q10 during statin therapy","volume":"40","author":"Levy","year":"2006","journal-title":"Ann. Pharmacother"},{"key":"B88","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1212\/01.wnl.0000277657.95487.1c","article-title":"Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease","volume":"69","author":"Li","year":"2007","journal-title":"Neurology"},{"key":"B89","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.4049\/jimmunol.0900101","article-title":"Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by V\u00ce\u00b39V\u00ce\u00b4 2 T Cells","volume":"182","author":"Li","year":"2009","journal-title":"J. Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1161\/CIRCULATIONAHA.111.028571","article-title":"Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?","volume":"123","author":"Liao","year":"2011","journal-title":"Circulation"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1021\/jm201657x","article-title":"Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase \u00e2\u20ac\u201c apoptosis and inhibition of ERK Phosphorylation in multiple myeloma cells","volume":"55","author":"Lin","year":"2012","journal-title":"J. Med. Chem"},{"key":"B92","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/cbdd.12121","article-title":"Farnesyl diphosphate synthase in hibitors from in silico screening","volume":"81","author":"Lindert","year":"2013","journal-title":"Chem. Bio. Drug Des"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B94","doi-asserted-by":"publisher","first-page":"18750","DOI":"10.1074\/jbc.M112.351254","article-title":"Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e201302011","DOI":"10.5936\/csbj.201302011","article-title":"Current progress in structure-based rational drug design marks a new mindset in drug discovery","volume":"5","author":"Lounnas","year":"2013","journal-title":"Comput. Struct. Biotechnol. J"},{"key":"B96","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1021\/jm9507340","article-title":"Alpha-phosphonosulfonic acids: potent and selective inhibitors of squalene synthase","volume":"39","author":"Magnin","year":"1996","journal-title":"J. Med. Chem"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1021\/jm00014a012","article-title":"1,1-bisphosphonate squalene synthase inhibitors: interplay between the isoprenoid subunit and the diphosphate surrogate","volume":"38","author":"Magnin","year":"1995","journal-title":"J. Med. Chem"},{"key":"B98","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1113\/jphysiol.2008.164699","article-title":"Blunted Akt\/FOXO signaling and activation of genes controlling atrophy and fuel use in statin myopathy","volume":"587","author":"Mallinson","year":"2009","journal-title":"J. Physiol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/pcan.2012.9","article-title":"Zoledronic acid influences growth migration and invasive activity of prostate cancer cells in vitro","volume":"15","author":"Mani","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B100","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/2013.jamaneurol.405","article-title":"The aging brain and cognition-contribution of vascular injury and \u00ce\u00b1\u00ce\u00b2 to mild cognitive dysfunction","volume":"70","author":"Marchant","year":"2013","journal-title":"JAMA Neurol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1021\/jm0702884","article-title":"Synthesis and biological evaluation of \u00ce\u00b1-Halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate","volume":"50","author":"Marma","year":"2007","journal-title":"J. Med. Chem"},{"key":"B102","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1006\/bbrc.1999.1404","article-title":"Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis","volume":"263","author":"Martin","year":"1999","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"B103","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1021\/jm200763k","article-title":"Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents","volume":"54","author":"Matralis","year":"2011","journal-title":"J. Med. Chem"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1021\/jm401842e","article-title":"Design of novel potent antihyperlipidemic agents with antioxidant\/anti-inflammatory properties. Exploiting phenothiazine's strong antioxidant activity","volume":"57","author":"Matralis","year":"2014","journal-title":"J. Med. Chem"},{"key":"B105","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/sj.bjp.0705331","article-title":"Squalene synthase inhibitors","volume":"139","author":"Menys","year":"2003","journal-title":"Br. J. Pharmacol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0968-0896(01)00289-9","article-title":"Syntheses of fused heterocyclic compounds and their inhibitory activities for squalene synthase","volume":"10","author":"Miki","year":"2002a","journal-title":"Bioorg. Med. Chem"},{"key":"B107","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0968-0896(01)00290-5","article-title":"Novel 4,1-benzoxazepinederivatives with potent squalene synthase inhibitory activities","volume":"10","author":"Miki","year":"2002b","journal-title":"Bioorg. Med. Chem"},{"key":"B108","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1021\/jm020234o","article-title":"Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis","volume":"45","author":"Miki","year":"2002c","journal-title":"J. Med. Chem"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.bone.2009.08.010","article-title":"The level ofATP analogs and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro","volume":"45","author":"Mitrofan","year":"2009","journal-title":"Bone"},{"key":"B110","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/jb\/mvm144","article-title":"Human geranylgeranyl diphosphate is an octamer in solution","volume":"142","author":"Miyagi","year":"2007","journal-title":"J. Biochem"},{"key":"B111","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","article-title":"A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates","volume":"147","author":"M\u00c3\u00b6nkk\u00c3\u00b6nen","year":"2006","journal-title":"Br. J. Pharmacol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"B113","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1600-065X.2006.00479.x","article-title":"Nonpeptide antigens, presentation mechanisms, and immunological memory of human V\u00ce\u00b32V\u00ce\u00b4 2 T cells: discriminating friends from foe through the recognition of prenyl pyrophosphate antigens","volume":"215","author":"Morita","year":"2007","journal-title":"Immunol. Rev"},{"key":"B115","volume-title":"Amine Bis- and Tri-Carbocyclic Alkane and Bis-Aryl Squalene Synthase Inhibitors. Rhone-Poulenc Rorer Pharmaceuticals Inc","author":"Morris","year":"1995"},{"key":"B116","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3727\/096504010X12671222663638","article-title":"Zoledronate stimulates \u00ce\u00b3\u00ce\u00b4 T cells in prostate cancer patients","volume":"18","author":"Naoe","year":"2010","journal-title":"Oncol. Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nchembio.149","article-title":"Analysis of the eukaryotic prenylome by isoprenoid affinity tagging","volume":"5","author":"Nguyen","year":"2009","journal-title":"Nat. Chem. Biol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.bjp.0705332","article-title":"Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro","volume":"139","author":"Nishimoto","year":"2003a","journal-title":"Br. J. Pharmacol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.bcp.2003.08.011","article-title":"Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes","volume":"66","author":"Nishimoto","year":"2003b","journal-title":"Biochem. Pharmacol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.taap.2007.05.005","article-title":"Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs","volume":"223","author":"Nishimoto","year":"2007","journal-title":"Toxicol. Appl. Pharmacol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000082918","article-title":"Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis","volume":"67","author":"Notarnicola","year":"2004","journal-title":"Oncology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1055\/s-2003-43060","article-title":"Cholesterol and tau Protein \u00e2\u20ac\u201c Findings in Alzheimer's and niemann pick c's diseases","volume":"36","author":"Ohm","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1021\/cb300189b","article-title":"Coloidal aggregattion affects the efficacy of anticancer drugs in cell culture","volume":"7","author":"Owen","year":"2012","journal-title":"ACS Chem. Biol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"30610","DOI":"10.1074\/jbc.M004132200","article-title":"Crystal structure of human squalene synthase: a key enzyme in cholesterol biosynthesis","volume":"275","author":"Pandit","year":"2000","journal-title":"J. Biol. Chem"},{"key":"B124","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1472-6807-12-32","article-title":"Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure","volume":"12","author":"Park","year":"2012","journal-title":"BMC Struct. Biol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1107\/S2053230X14002106","article-title":"Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate","volume":"70","author":"Park","year":"2014","journal-title":"Acta Crystallogr. F Struct. Biol. Commun"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.bmcl.2008.02.009","article-title":"Design and structure\u00e2\u20ac\u201cactivity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and dihydropyridin-2-ones","volume":"18","author":"Peukert","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B127","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1016\/S0021-9258(17)34489-7","article-title":"Farnesyl pyrophosphate synthetase. Mechanistic studies of the 1\u00e2\u20ac\u00b2-4 coupling reaction with 2-fluorogeranyl pyrophosphate","volume":"253","author":"Poulter","year":"1978","journal-title":"J. Biol. Chem"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1021\/ja00192a036","article-title":"Squalene synthetase inhibition by ammonium analogues of carbocationic intermediates in the conversion of presqualene diphosphate to squalene","volume":"111","author":"Poulter","year":"1989","journal-title":"J. Am. Chem. Soc"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1021\/jm00062a026","article-title":"N-(arylalkyl)farnesylamines: new potent squalene synthase inhibitors","volume":"36","author":"Prashad","year":"1993","journal-title":"J. Med. Chem"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"B131","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.bcp.2009.10.003","article-title":"Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells","volume":"79","author":"R\u00c3\u00a4ikk\u00c3\u00b6nen","year":"2010","journal-title":"Biochem. Pharmacol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.bbrc.2011.03.070","article-title":"Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonate in cultured cells","volume":"407","author":"R\u00c3\u00a4ikk\u00c3\u00b6nen","year":"2011","journal-title":"Bioche. Biophys. Res. Commun"},{"key":"B133","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1021\/bi00672a009","article-title":"Crystallization and partial characterization of prenyltransferase from avian liver","volume":"14","author":"Reed","year":"1975","journal-title":"Biochemistry"},{"key":"B134","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3233\/JAD-2006-10408","article-title":"Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid","volume":"10","author":"Riekse","year":"2006","journal-title":"J. Alzheimers Dis"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/01.RES.0000196564.18314.23","article-title":"Rho GTPases, statins, and nitric oxide","volume":"97","author":"Rikitake","year":"2005","journal-title":"Circ. Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann. Oncol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","article-title":"Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis","volume":"42","author":"Rizzoli","year":"2008","journal-title":"Bone"},{"key":"B138","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/cmdc.200500059","article-title":"Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs","volume":"1","author":"Rondeau","year":"2006","journal-title":"ChemMedChem"},{"key":"B139","doi-asserted-by":"publisher","first-page":"14093","DOI":"10.1074\/jbc.272.22.14093","article-title":"Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.","volume":"272","author":"Rowell","year":"1997","journal-title":"J. Biol. Chem"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/JCO.2006.05.9808","article-title":"Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors","volume":"24","author":"Rowinsky","year":"2006","journal-title":"J. Clin. Oncol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"B142","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"B143","doi-asserted-by":"publisher","first-page":"37046","DOI":"10.1074\/jbc.274.52.37046","article-title":"The Neurite Retraction Induced by Lysophosphatidic Acid Increases Alzheimer's Disease-like Tau Phosphorylation","volume":"274","author":"Sayas","year":"1999","journal-title":"J. Biol. Chem"},{"key":"B145","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/bjp.2008.143","article-title":"Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage\/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions","volume":"154","author":"Shiomi","year":"2008","journal-title":"Br. J. Pharmacol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jconrel.2010.04.028","article-title":"Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells","volume":"146","author":"Shmeeda","year":"2010","journal-title":"J. Control. Release"},{"key":"B147","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.bmc.2006.02.010","article-title":"Synthesis and biological activity of isoprenoid bisphosphonates","volume":"14","author":"Shull","year":"2006","journal-title":"Bioorg. Med. Chem"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/anie.201204964","article-title":"Alzheimer's disease, cholesterol, and statins: the junction of important metabolic pathways","volume":"52","author":"Silva","year":"2013","journal-title":"Angew. Chem. Int. Ed"},{"key":"B149","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/0091270002239824","article-title":"The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function","volume":"43","author":"Skerjanec","year":"2003","journal-title":"J. Clin. Pharmacol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1073\/pnas.91.8.3044","article-title":"Yeast farnesyl-diphosphate synthase: site-directed mutagenesis of residues in highly conserved prenyltransferase domains I and II","volume":"91","author":"Song","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B151","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncb2936","article-title":"Metabolic control of YAP and TAZ by the mevalonate pathway","volume":"16","author":"Sorrentino","year":"2014","journal-title":"Nat. Cell Biol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1158\/1078-0432.CCR-08-2658","article-title":"Phase II trial of tipifarnib plus neoadjuvant doxorubicin- cyclophosphamide in patients with clinical stage IIB-IIC breast cancer","volume":"15","author":"Sparano","year":"2009","journal-title":"Clin. Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1749-6632.1997.tb48466.x","article-title":"Coronary artery disease, hypertension, apoE and cholesterol: a link to Alzheimer's diseases?","volume":"826","author":"Sparks","year":"1997","journal-title":"Ann. N.Y. Acad. Sci"},{"key":"B154","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/0197-4580(90)90024-T","article-title":"Cortical senile plaques in coronary artery disease, aging and Alzheimer's diseases","volume":"11","author":"Sparks","year":"1990","journal-title":"Neurobiol. Aging"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1021\/bi401329a","article-title":"Structure and function of human dnaj homologues subfamily A Member 1 (DNAJA1) and its relationship to pancreatic cancer","volume":"53","author":"Stark","year":"2014","journal-title":"Biochemistry"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1161\/CIRCULATIONAHA.110.975284","article-title":"Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia","volume":"123","author":"Stein","year":"2011","journal-title":"Circulation"},{"key":"B157","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1021\/jm010412y","article-title":"Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiparasitic agents","volume":"45","author":"Szabo","year":"2002","journal-title":"J. Med. Chem"},{"key":"B158","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1152\/physrev.2001.81.1.153","article-title":"Small GTP-binding proteins","volume":"81","author":"Takai","year":"2001","journal-title":"Physiol. Rev"},{"key":"B159","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0079-6603(00)65005-5","article-title":"Squalene synthase: structure and regulation","volume":"65","author":"Tansey","year":"2001","journal-title":"Proq. Nucleic Acid Res. Mol. Biol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1073\/pnas.93.26.15018","article-title":"Regulation of product chain length by isoprenyl diphosphate synthase","volume":"93","author":"Tarshis","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B161","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1124\/jpet.107.126375","article-title":"ER2306 [2-(4-Biphenyl)-4-methyl- octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit","volume":"323","author":"Tavridou","year":"2007","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"B162","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/FJC.0b013e31817885fe","article-title":"Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit","volume":"51","author":"Tavridou","year":"2008","journal-title":"J. Cardiovasc. Pharmacol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nbt0504-513","article-title":"Structure-aided drug design's next generation","volume":"22","author":"Thiel","year":"2004","journal-title":"Nat. Biotechnol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00345-012-0844-y","article-title":"Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in diseases progression?","volume":"31","author":"Todenh\u00c3\u00b6fer","year":"2013","journal-title":"World J. Urol"},{"key":"B165","volume-title":"Cycloalkyl Amine Bis-Aryl Squalene Synthase Inhibitors. Rhone-Poulenc Rorer Pharmaceuticals Inc","author":"Ullrich","year":"1994"},{"key":"B166","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1006\/abbi.1998.0704","article-title":"Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A","volume":"355","author":"Vaidya","year":"1998","journal-title":"Arch. Biochem. Biophys"},{"key":"B167","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.1158\/1078-0432.CCR-07-2184","article-title":"The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members","volume":"13","author":"Verdine","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.4049\/jimmunol.1002697","article-title":"Indirect stimulation of human V\u00ce\u00b32V\u00ce\u00b4 2 T cells through alterations in isoprenoid metabolism","volume":"187","author":"Wang","year":"2011","journal-title":"J. Immunol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/jpet.110.175521","article-title":"Bisphosphosphonates induce autophagy by depleting geranylgeranyl diphosphate","volume":"337","author":"Wasko","year":"2011","journal-title":"J. Pharamacol. Exp. Ther"},{"key":"B170","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1124\/dmd.108.021071","article-title":"Biodistribution and plasma protein binding of zoledronic acid","volume":"36","author":"Weiss","year":"2008","journal-title":"Drug Metab. Dispos"},{"key":"B171","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J. Biol. Chem"},{"key":"B172","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1741-7015-5-20","article-title":"Simvastatin is associated with a reduced incidence of dementia and Parkinson's diseases","volume":"5","author":"Wolozin","year":"2007","journal-title":"BMC Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/jnc.12637","article-title":"Cholesterol as a causative factor in Alzheimer's diseases: a debatable hypothesis","volume":"129","author":"Wood","year":"2014a","journal-title":"J. Neurochem"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-014-8647-3","article-title":"Statins and neuroprotection: basic pharmacology needed","author":"Wood","year":"2014b","journal-title":"Mol. Neurobiol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1074\/jbc.272.7.3944","article-title":"Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-i and protein farnesyltransferase and its consequence on the specificity of protein prenylation","volume":"272","author":"Yokoyama","year":"1997","journal-title":"J. Biol. Chem"},{"key":"B176","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1194\/jlr.R500011-JLR200","article-title":"Prelamin, A., Zmpste24, misshapen cell nuclei, and progeria \u00e2\u20ac\u201c new evidence suggesting that protein farnesylation could be important for diseases pathogenesis","volume":"46","author":"Young","year":"2005","journal-title":"J. Lipid Res"},{"key":"B177","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/1471-2407-14-248","article-title":"GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis","volume":"14","author":"Yu","year":"2014","journal-title":"BMC Cancer"},{"key":"B178","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1021\/ja808285e","article-title":"Lipophilic bisphosphonates as dual Farnesyl\/Geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation","volume":"131","author":"Zhang","year":"2009","journal-title":"J. Am. Chem. Soc"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/anie.200905933","article-title":"Lipophilic pyridinium bisphosphonates: potent \u00ce\u00b3\u00ce\u00b4 T cell stimulators","volume":"49","author":"Zhang","year":"2010","journal-title":"Angew. Chem. Int. Ed"},{"key":"B180","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1021\/jm060280e","article-title":"Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines","volume":"49","author":"Zhang","year":"2006","journal-title":"J. Med. Chem"}],"container-title":["Frontiers in Chemistry"],"original-title":[],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T22:13:25Z","timestamp":1746310405000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fchem.2014.00050\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,22]]},"references-count":181,"URL":"https:\/\/doi.org\/10.3389\/fchem.2014.00050","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,22]]}}}